The Investor
27 Apr 2026, 19:26
Thermo Fisher Scientific has agreed to sell its microbiology business to Astorg for approximately $1.075 billion, including cash and a $50 million seller note.
The divested unit, which provides antimicrobial testing and culture media solutions for clinical, pharmaceutical, and food safety applications, generated $645 million in revenue in 2025 and is part of Thermo Fisher’s Specialty Diagnostics segment.
The company said the transaction reflects active portfolio management and will provide additional capital to invest in higher-growth areas and enhance shareholder value. The deal is expected to close in the second half of 2026, subject to regulatory approvals and customary conditions.
Thermo Fisher noted the sale will have a modest negative impact on adjusted earnings per share in the first full year after closing.
Business Wire
The divested unit, which provides antimicrobial testing and culture media solutions for clinical, pharmaceutical, and food safety applications, generated $645 million in revenue in 2025 and is part of Thermo Fisher’s Specialty Diagnostics segment.
The company said the transaction reflects active portfolio management and will provide additional capital to invest in higher-growth areas and enhance shareholder value. The deal is expected to close in the second half of 2026, subject to regulatory approvals and customary conditions.
Thermo Fisher noted the sale will have a modest negative impact on adjusted earnings per share in the first full year after closing.
Business Wire
